Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Absci Corporation - Common Stock
(NQ:
ABSI
)
2.930
-0.070 (-2.33%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 15, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Absci Corporation - Common Stock
< Previous
1
2
3
Next >
Absci Reports Business Updates and Second Quarter 2025 Financial and Operating Results
August 12, 2025
From
Absci Corporation
Via
GlobeNewswire
Almirall and Absci Expand AI Drug Creation Collaboration Adding a Second Dermatology Target
August 07, 2025
From
Absci Corporation
Via
GlobeNewswire
Absci to Report Business Updates and Second Quarter 2025 Financial and Operating Results on August 12, 2025
July 30, 2025
From
Absci Corporation
Via
GlobeNewswire
Absci Announces Pricing of Public Offering of Common Stock
July 24, 2025
From
Absci Corporation
Via
GlobeNewswire
Absci Announces Proposed Public Offering of Common Stock
July 24, 2025
From
Absci Corporation
Via
GlobeNewswire
iRhythm Technologies Announces Board Member Retirements and New Director Appointments
July 07, 2025
From
iRhythm
Via
GlobeNewswire
Absci Appoints Biopharma Leader Mary Szela to Board of Directors
July 07, 2025
Former Abbott executive who led the US launch and global expansion of Humira® adds three decades of commercial and clinical leadership expertise
From
Absci Corporation
Via
GlobeNewswire
Absci to Participate in Upcoming Investor Conferences
May 20, 2025
From
Absci Corporation
Via
GlobeNewswire
Absci Reports Business Updates and First Quarter 2025 Financial and Operating Results
May 13, 2025
From
Absci Corporation
Via
GlobeNewswire
Absci Announces First Participants Dosed in Phase 1 Clinical Trial of ABS-101, a Potential Best-In-Class anti-TL1A Antibody for the Treatment of Inflammatory Bowel Disease
May 13, 2025
From
Absci Corporation
Via
GlobeNewswire
Absci to Report Business Updates and First Quarter 2025 Financial and Operating Results on May 13, 2025
April 14, 2025
From
Absci Corporation
Via
GlobeNewswire
Absci to Participate in Upcoming Investor Conferences
March 26, 2025
From
Absci Corporation
Via
GlobeNewswire
Absci Reports Business Updates and Fourth Quarter and Full Year 2024 Financial and Operating Results
March 18, 2025
From
Absci Corporation
Via
GlobeNewswire
Absci to Report Business Updates and Fourth Quarter and Full Year 2024 Financial and Operating Results on March 18, 2025
March 04, 2025
From
Absci Corporation
Via
GlobeNewswire
Absci Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
March 04, 2025
From
Absci Corporation
Via
GlobeNewswire
Absci to Participate in the KeyBanc Capital Markets Healthcare Forum
March 04, 2025
From
Absci Corporation
Via
GlobeNewswire
Absci to Participate in the TD Cowen 45th Annual Health Care Conference
February 18, 2025
From
Absci Corporation
Via
GlobeNewswire
Absci to Participate in the Guggenheim Securities SMID Cap Biotech Conference
January 22, 2025
From
Absci Corporation
Via
GlobeNewswire
Absci and Owkin Synergize Leading TechBio Platforms to Advance Generative AI Drug Discovery
January 10, 2025
Collaboration combines Owkin’s novel AI target discovery and agentic AI expertise with Absci’s leading AI de novo design models to accelerate the discovery and design of potential first-in-class...
From
Absci Corporation; Owkin
Via
GlobeNewswire
Absci and AMD Announce Collaboration and Strategic Investment to Accelerate the Future of AI Drug Discovery
January 08, 2025
$20 Million Equity Investment from AMD Strengthens Absci’s Leadership in AI Drug Discovery and Further Expands Biopharma Adoption of AMD Instinct Accelerators and ROCm Software
From
Absci Corporation
Via
GlobeNewswire
Absci and Invetx Partner to Bring Generative AI Drug Creation Platform to Animal Health
January 06, 2025
Collaboration leverages Absci’s leading generative AI Drug Creation models to design a novel antibody Half-Life Extension (HLE) platform for animal health applications
From
Absci Corporation; Invetx
Via
GlobeNewswire
Absci to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
January 02, 2025
From
Absci Corporation
Via
GlobeNewswire
Absci Highlights Progress and Updates Across Proprietary Pipeline and Leading AI Platform at 2024 R&D Day
December 12, 2024
From
Absci Corporation
Via
GlobeNewswire
Absci to Participate in the 36th Annual Piper Sandler Healthcare Conference
November 21, 2024
From
Absci Corporation
Via
GlobeNewswire
Absci Reports Business Updates and Third Quarter 2024 Financial and Operating Results
November 12, 2024
From
Absci Corporation
Via
GlobeNewswire
Absci to Host R&D Day on December 12, 2024
November 07, 2024
From
Absci Corporation
Via
GlobeNewswire
Absci and Twist Bioscience Collaborate to Design Novel Antibody using Generative AI
October 31, 2024
Collaboration brings together Absci’s Generative AI drug creation platform with Twist’s DNA synthesis platform to accelerate the design of a novel therapeutic antibody
From
Absci Corporation
Via
GlobeNewswire
Absci to Participate in Upcoming Investor Conferences
October 24, 2024
From
Absci Corporation
Via
GlobeNewswire
Absci to Report Business Updates and Third Quarter 2024 Financial and Operating Results on November 12, 2024
October 15, 2024
From
Absci Corporation
Via
GlobeNewswire
Absci to Participate in Upcoming Investor Conferences
August 21, 2024
From
Absci Corporation
Via
GlobeNewswire
< Previous
1
2
3
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms Of Service
.